J Clin Invest: A persistent cellular immune disorder occurs in patients recovering from SARS-CoV-2 infection

SARS-CoV-2 causes a variety of pathological manifestations, leads to higher mortality rates, requires understanding the pathogenesis of the disease, providing information for vaccine design, and studying potential immune characteristics.
a recent study published in J Clin Invest, researchers looked at the subgengies of immune cells in both hospitalized and non-hospitalized patients and found that patients with immune disorders after SARS-CoV-2 infection took longer to develop, and more research was needed to investigate immune disorders in patients.
increased frequency of T-cell activity markers (CD69, OX40, HLA-DR, and CD154) in hospitalized patients, while other T-cell activity/depletion markers (PD-L1 and TIGIT) remained elevated in hospitalized and non-hospitalized patients.
B cells had similar activation/depletion patterns, with an increase in the frequency of CD69 and CD95 during hospitalization, followed by an increase in the frequency of PD1 in non-hospitalized individuals.
interestingly, many of these changes increased over time in non-hospitalized longitudinal samples, indicating a long period of time after SARS-CoV-2 infection.
in non-hospitalized patients was found to be positively related to age in changes in T-cell activity/depletion.
the expression of signs of active and depletion of seriously infected persons.
chart, combined with the frequency of activation or failure of CD4-T cells, CD8-T cells, and B-cell markers in ICU patients, these data indicate that the duration of immune disorders after SARS-CoV-2 infection is longer, highlighting the need for more research to investigate immune disorders in nursing home patients.